Immutep IMMP
NASDAQ IMMP
$4.35 -0.19 (-4.19%)
At close: Oct 2, 2026 · 4:00 PM EDT

Immutep (IMMP) Return on Sales [ROS] (2016 - 2017)

Updated

Immutep (IMMP) reported Return on Sales [ROS] of -545.26% for the year ended Jun 30, 2026, up 49.74 percentage points from -595.00% a year earlier.

Analysis

Immutep (IMMP) Return on Sales [ROS] (2016 - 2017) Analysis & Trends

Dating back to the year ended Jun 30, 2010, Immutep's Return on Sales [ROS] record includes 13 years.

  • Return on Sales [ROS] has a four-year change of +18415.48 percentage points (years ended Jun 2022 to Jun 2026).
  • The figure for the year ended Jun 30, 2026 ranks as the highest annual Return on Sales [ROS] since the year ended Jun 30, 2020.
  • According to Business Quant data, Return on Sales [ROS] came in at -595.00% in the year ended Jun 30, 2025 and -18960.74% in the year ended Jun 30, 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Immutep 31.76 Mn 31.76 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2017 -1,215.15%
Mar 31, 2017 -137.35%
Mar 31, 2016 -763.62%
API Access

Immutep Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=IMMP&period=max&api_key=YOUR_API_KEY